First Time Loading...

Moderna Inc

Watchlist Manager
Moderna Inc Logo
Moderna Inc
Price: 103.29 USD +3.01% Market Closed
Updated: Oct 1, 2023

Intrinsic Value

Intrinsic Value History
Moderna Inc

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Moderna Inc's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis


Balance Sheet Decomposition
Moderna Inc

Current Assets 10.6B
Cash & Short-Term Investments 8.5B
Receivables 688m
Other Current Assets 1.5B
Non-Current Assets 11.3B
Long-Term Investments 6.1B
PP&E 2.4B
Other Non-Current Assets 2.8B
Current Liabilities 3.1B
Accounts Payable 310m
Accrued Liabilities 1.5B
Other Current Liabilities 1.3B
Non-Current Liabilities 1.8B
Long-Term Debt 843m
Other Non-Current Liabilities 969m
Fundamental Scores

MRNA Profitability Score
Profitability Due Diligence

Moderna Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE

Moderna Inc's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

MRNA Solvency Score
Solvency Due Diligence

Moderna Inc's solvency score is 98/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Negative Net Debt

Moderna Inc's solvency score is 98/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRNA Price Targets Summary
Moderna Inc

Wall Street analysts forecast MRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRNA is 185.1 USD with a low forecast of 68.68 USD and a high forecast of 451.5 USD.

Price Target
68.68 USD
34% Downside
Price Target
185.1 USD
79% Upside
Price Target
451.5 USD
337% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


MRNA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MRNA Return Decomposition
Main factors of price return

What is price return decomposition?

MRNA Price
Moderna Inc

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 149.81%
Standard Deviation of Annual Returns 227.11%
Max Drawdown -80%
Shares Statistics
Market Capitalization 39.4B USD
Shares Outstanding 381 209 000
Percentage of Shares Shorted 6.31%


Last Video News
Moderna Inc

Other Videos

Last Important Events
Moderna Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.


Sentiment Analysis
Moderna Inc

Last 7 Days
Last 30 Days
Last 90 Days

Company Profile

Moderna Inc Logo
Moderna Inc


United States of America



Market Cap

39.4B USD

Dividend Yield



Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 2,700 full-time employees. The company went IPO on 2018-12-07. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The company is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The firm develops technologies that enable the development of mRNA medicines for diverse applications. The company has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The firm develops technologies that enable the development of mRNA medicines.


200 Technology Sq




2 700


Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board
Dr. Noubar B. Afeyan Ph.D.
CEO & Director
Mr. Stephane Bancel
Dr. Stephen Hoge M.D.
Chief Legal Officer & Corp. Sec.
Ms. Shannon Thyme Klinger
Pres of Strategic Partnerships & Enterprise Expansion
Mr. Juan Andres
Chief Financial Officer
Mr. James M. Mock
Show More
Chief Technical Operations & Quality Officer
Dr. Jerh Collins Ph.D.
Chief Information Officer
Dr. John V. W. Reynders Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board
Dr. Melissa J. Moore Ph.D.
Sr. VP & Head of Investor Relations
Ms. Lavina Talukdar CFA
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one MRNA stock?

The intrinsic value of one MRNA stock under the Base Case scenario is 39.47 USD.

Is MRNA stock undervalued or overvalued?

Compared to the current market price of 103.29 USD, Moderna Inc is Overvalued by 62%.